Sessa Capital’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.97M Hold
2,198,457
– – 0.1% 27
2026
Q2
$8.57M Hold
2,198,457
– – 0.14% 26
2026
Q1
$8.42M Hold
2,198,457
– – 0.15% 30
2025
Q4
$8.22M Hold
2,198,457
– – 0.15% 26
2025
Q3
$4.42M Buy
2,198,457
+1,740,000
+380% +$3.93M 0.1% 25
2025
Q2
$805K Hold
458,457
– – 0.02% 27
2025
Q1
$624K Hold
458,457
– – 0.02% 28
2024
Q4
$1.74M Hold
458,457
– – 0.06% 25
2024
Q3
$1.24M Hold
458,457
– – 0.05% 28
2024
Q2
$1.42M Hold
458,457
– – 0.04% 26
2024
Q1
$2.08M Hold
458,457
– – 0.05% 27
2023
Q4
$3.15M Buy
+458,457
New +$3.84M 0.11% 22

Other funds holding SABS

Sessa Capital's SABS Position: Q3 2026 in Review

Sessa Capital held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 2,198,457 shares worth $6.97M. The position accounts for 0.1% of the portfolio, ranked #27.

Sessa Capital first reported a position in SABS in Q4 2023 and has held it in 12 quarters since. The position peaked at $8.57M in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Sessa Capital held 2,198,457 shares of SAB Biotherapeutics worth $6.97M as of Q3 2026.
  • Sessa Capital left its SAB Biotherapeutics share count unchanged in Q3 2026.
  • SAB Biotherapeutics made up 0.1% of Sessa Capital's portfolio in Q3 2026, its #27 holding.
  • Sessa Capital first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 12 quarters since.
  • Sessa Capital's SAB Biotherapeutics position peaked at $8.57M in Q2 2026.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Sessa Capital's 13F filing for Q3 2026, filed 16 Nov 2026.